In a small cohort of patients diagnosed with CML, the response to imatinib in R61C (rs12208357) heterozygote individuals was comparable to that achieved by patients carrying wild-type OCT1 [66]. Here, SLC22A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.